小剂量复方倍他米松联合富血小板血浆在膝骨关节炎中的应用效果OA
Effect of Low-Dose Compound Betamethasone Combined with Platelet Rich Plasma in the Treatment of Knee Osteoarthritis
目的:探讨小剂量复方倍他米松联合富血小板血浆(PRP)在膝骨关节炎(KOA)中的应用效果.方法:选取2021年12月～2022年12月期间某院收治的92例KOA患者作为研究对象,采用简单随机抽样法分为对照组和观察组,每组46例.所有患者均给予KOA常规药物(硫酸氨基葡萄糖胶囊)治疗,对照组患者给予PRP治疗,观察组在对照组基础上加用小剂量复方倍他米松注射液.比较两组患者疼痛情况[视觉模拟评分法(VAS)]、膝关节功能恢复情况[Lysholm膝关节功能评分表(LKSS)]、膝关节活动度[关节活动度(ROM)、西安大略和麦克马斯特大学骨关节炎指数(WOMAC)]、日常生活能力[Barthel指数(BI)]、步行能力、临床疗效及不良反应发生情况.结果:治疗后,两组患者VAS评分均降低(P<0.05),且观察组低于对照组(P<0.05);LKSS评分均升高(P<0.05),且观察组高于对照组(P<0.05);关节主动活动度、关节被动活动度均升高(P<0.05),且观察组高于对照组(P<0.05);WOMAC评分均降低(P<0.05),且观察组低于对照组(P<0.05);BI、步行能力得分均升高(P<0.05),且观察组均高于对照组(P<0.05).观察组患者治疗总有效率(95.65%)高于对照组(80.43%,P<0.05).两组患者不良反应发生情况比较无统计学差异(χ2=0.212,P=0.646).结论:在KOA常规药物治疗基础上联合PRP、小剂量复方倍他米松治疗KOA患者临床疗效较好,可显著减轻患者疼痛,改善膝关节活动情况,促进膝关节功能恢复,提高日常生活能力和步行能力.
Objective:To investigate the application effect of low-dose compound betamethasonein combined with platelet rich plasma(PRP)the treatment of knee osteoarthritis(KOA).Methods:92 patients with KOA and admitted to the hospital between December 2021 and December 2022 were selected and assigned into the control group and the observation group using a simple random grouping method,with 46 cases in each group.All patients received the conventional drug for KOA(glucosamine sulfate capsules).The control group received PRP treatment,while the observation group additionally received low-dose compound betamethasone injection.The pain status[visual analogue scale(VAS),knee function recovery status[Lysholm knee score scale(LKSS)],knee joint activity[range of motion(ROM),Western Ontario and Mcmaster Universitiy osteoarthritis index(WOMAC)],daily living ability[Barthel index(BI)],walking ability,clinical efficacy and occurrence of adverse reactions were compared between the two groups.Results:After treatment,the VAS score decreased in both groups(P<0.05),with the observation group having a lower score than the control group(P<0.05).The LKSS score increased in both groups(P<0.05),with the observation group scoring higher than the control group(P<0.05).Both groups showed enhanced active and passive ranges of motion(P<0.05),with the observation group demonstrating higher ranges of motion(P<0.05).The WOMAC score decreased(P<0.05),with the observation group scoring lower than the control group(P<0.05).Both groups showed increased scores in BI and walking ability(P<0.05),with the observation group scoring higher than the control group(P<0.05).The total effective rate of treatment in the observation group(95.65%)was significantly higher than that in the control group(80.43%,P<0.05).There was no significant difference in the occurrence of adverse reactions between the two groups(χ2=0.212,P=0.646).Conclusion:The combination of PRP and low-dose compound betamethasone,in conjunction with conventional KOA drugs,demonstrates precise clinical efficacy in treating KOA patients.This treatment approach significantly reduces pain,enhances knee joint activity,promotes recovery of knee function,and improves daily living and walking abilities.
任国强;明海武;董卫兵;庄卫生
郑州颐和医院骨科,郑州 450000河南省人民医院骨科,郑州 450000
中医学
富血小板血浆复方倍他米松膝骨关节炎膝关节功能日常生活能力步行能力
platelet rich plasmacompound betamethasoneknee osteoarthritisknee functionability of daily livingwalking ability
《中国合理用药探索》 2024 (003)
68-74 / 7
河南省卫生和计划生育委员会(202102310452)
评论